Further assessment of the effects of SGLT-2 inhibitors in people with CKD remains important as DAPA-CKD reported limited information about effects in people without DM [25], and excluded certain causes of kidney disease, and people with low levels of albuminuria (who constitute the majority of people with CKD) [18, 23, 24]. The gene discussed is SLC5A2; the disease is chronic kidney disease.